Video Library
Learn about unique perspectives and experiences with desmoid tumors and OGSIVEO.
Unmet Need
Watch Dr. Federman and Dr. Randall discuss the burden of desmoid tumors, patient characteristics, signs of disease progression, and management considerations.
“[Desmoid tumors] can cause a lot of problems. So, we as physicians, need to really listen to our patients and their journey thus far when they come to see us. Are their symptoms getting worse? Is the tumor growing based on objective criteria like MRI or CT, is it impairing their function?”
Dr. Randall, M.D., FACS, Professor and Chair, Department of Orthopedic Surgery,
University of California, Davis School of Medicine
Review the OGSIVEO Overview for Healthcare Professionals for a summary of information about OGSIVEO, including clinical data, guideline recommendations, and information about adverse events.
DownloadOGSIVEO Overview and Patient Case Study
Watch Dr. Federman and Dr. Randall discuss the DeFi trial design, review efficacy and safety results, and present a hypothetical case study of a patient treated with OGSIVEO.
“The route of entry into the health care system is often through orthopedic surgeons and surgical oncologists and sometimes general community surgeons. And so, this is where it’s really important that these patients are presented, in a multidisciplinary format and that there are real experts at the table that have seen these patients before.”
Dr. Noah Federman, M.D. Medical Director, Clinical Translational Research Center Director, Pediatric Bone and Soft Tissue Program, UCLA Los Angeles, California
Review the OGSIVEO Overview for Healthcare Professionals for a summary of information about OGSIVEO, including clinical data, guideline recommendations, and information about adverse events.
DownloadInsights from a patient, oncologist, and pharmacist
Hear from Leif, a desmoid tumor patient, as he discusses his journey, from initial diagnosis to finding a treatment approach that works for him. He’s joined by his medical oncologist, Dr. Fade Mahmoud, and clinical pharmacist, Alexis Spence, who share their experiences and role in treating patients like Leif as part of a multidisciplinary care team.
“When I started on OGSIVEO, me and Dr. Mahmoud had talked about a care plan. And at the three-month mark, we had done blood work, and did an MRI and noticed that the tumor was starting to reduce in size at that point. And then at the six-month mark, we had noticed we were probably 50% smaller than when we had started. The tumor’s very minimal at this point.”
Leif, a patient taking OGSIVEO
This video represents the personal experience of Leif only. Individual results may vary.
Review the OGSIVEO Overview for Healthcare Professionals for a summary of information about OGSIVEO, including clinical data, guideline recommendations, and information about adverse events.
DownloadDownload the DeFi Study Publication
OGSIVEO was evaluated in DeFi—the largest completed Phase 3 trial of an FDA-approved therapy in adult patients with desmoid tumors. Review the results of this landmark study in The New England Journal of Medicine.
